Australian researchers have found pain experiences and management techniques change over time in a longitudinal study of people with MS.
Pain is a common symptom of MS and can be due to the inflammation related to the MS disease process or complications arising from the disease. In a recent study by A/Prof Fary Khan from Melbourne, 94 people with MS were followed over seven years to assess pain experiences and management techniques.
A/Prof Kahn is the Director of the Rehabilitation Medicine Department at the Royal Melbourne Hospital and received the MSRA Ian Ballard Travel Fellowship to facilitate her international research collaborations in 2010.
A new study using the Ausimmune cohort has investigated lifestyle habits as risk factors of first demyelinating events, the precursor to MS.
A new Australian study using the Ausimmune cohort has investigated lifestyle habits and blood pressure as risk factors of first clinical demyelinating events – the precursor episode to a definite diagnosis of MS. The Ausimmune study has been running since 2003 with foundation funding from MSRA and the USA National MS Society and has examined a large number of environmental factors and how they might affect risk.
US researchers have successfully completed a small safety trial of a new experimental treatment for MS which attempts to re-train the immune system.
In a study published this week in the journal Science Translational Medicine, researchers from Northwestern University have had promising results using a new treatment for people with MS.
Australian researchers have used an online survey to investigate the association of fish and omega 3 consumption with disease activity and quality of life in people with MS
Dr George Jelinek and colleagues at the St Vincent’s Hospital Emergency Practice Innovation Centre, Melbourne, have conducted a large study of dietary and lifestyle factors in people with MS to investigate the potential effects of fish consumption and omega 3 fatty acid consumption on disease activity and quality of life in people with MS.
The results have been published in the International Journal of Neuroscience (view the abstract here).
An anonymous online survey is being launched to gather information about spasticity treatment needs for people with MS and their carers.
Spasticity is a potentially disabling symptom for people with MS, and is estimated to be a significant problem for up to 80% of patients (1). Spasticity can cause spasms, walking problems and sleep problems as well as affecting personal activities of daily living (1).
New research shows that brain atrophy occurs within the first year after a first attack and predicts conversion to clinically definite MS.
Spanish researchers have investigated the short-term development of tissue-specific and global brain atrophy (brain volume loss) in people with clinically isolated syndrome (CIS).
The research was published in Multiple Sclerosis Journal (read the abstract).
In this issue of Next, we highlight some of the research projects being funded by MSRA and farewell our founding CEO as he heads into retirement.
To view the articles in Next 31, please click on the link below
MS treatments, Aubagio (teriflunomide) and Tecfidera (BG-12), and spasticity treatment, Sativex, under PBAC review at July meeting. Comments invited.
The Pharmaceutical Benefit Advisory Committee (PBAC) will consider three new MS medications for listing on the Pharmaceutical Benefits Scheme at their meeting in July. The PBAC is responsible for recommending to the government whether new drugs should be listed for reimbursement on the Pharmaceutical Benefits Scheme.
Research into MS prevention and treatment will receive a boost, with the Australian Government to invest a further $1 million to assist MSRA to continue its world class research over the next 4 years.
Research into multiple sclerosis (MS) prevention and treatment will receive a boost, with the Australian Government to invest a further $1 million to assist Multiple Sclerosis Research Australia (MSRA) to continue its world class research over the next 4 years.
'Every year around 1,000 Australians, mostly in their twenties to forties and disproportionately women, are diagnosed with MS,' the Health Minister Hon Tanya Plibersek MP said today.
A 16 year follow-up of patients from the original interferon-beta-1b clinical trial shows that those who received interferon early do better on measures of memory.
Declines in cognitive function are a relatively common feature in MS and have a significant impact on the social, emotional and family life of people with MS. Cognitive changes have also been shown to be one of the most significant factors affecting employment for many people with MS.
American scientists have achieved a breakthrough in human stem cell science by successfully using a ‘therapeutic cloning’ technique to generate human stem cells.
Despite success in other mammals the use of somatic cell nuclear transfer - ‘therapeutic cloning’ - to generate human stem cells has proved problematic. American scientists have now developed a technique to overcome the barriers and have successfully derived human stem cells from cloned human embryos.
The research was published in the top scientific journal Cell this week.
A NSW Upper House Inquiry has recommended changes to the law to allow medical use of cannabis and affordable access to pharmaceutical cannabis-based medications
A NSW Upper House General Purpose Standing Committee report on the inquiry into The use of cannabis for medical purposes was released on 15 May.
The Committee has made recommendations for changes in the State’s Drug Misuse and Trafficking Act to enable possession of small amounts of crude cannabis product for medicinal purposes.
The Committee also recommended that the NSW Government acts to encourage the Federal Government to facilitate affordable access to pharmaceutical cannabis-based products.
Recently published international research again highlights fatigue and cognitive symptoms rather than workplace discrimination are linked to lower levels of employment in people with MS.
Several international studies and previous research by the MSRA-funded MS Longitudinal Study have highlighted the much higher rate of unemployment in people with MS.
This month, three additional studies published in the journal Multiple Sclerosis by British, German and American research groups, further emphasise the extent and possible causes of the problem.